metaEvidence - overview

button bars forest bayes pooled summary circles


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
versus gemcitabine plus platin
	atezolizumab alone vs. gemcitabine plus platin	1	1.02 [0.83; 1.25], 1 RCT, I2=0% inconclusive result	-	-
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.83 [0.69; 1.00], 1 RCT, I2=0% unassessable degree of certainty	0.82 [0.70; 0.96], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	1	0.85 [0.73; 0.99], 1 RCT, I2=0% unassessable degree of certainty	0.89 [0.60; 1.32], 1 RCT, I2=0% inconclusive result	-
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	2	0.87 [0.72; 1.06], 1 RCT, I2=0% inconclusive result	0.86 [0.53; 1.39], 1 RCT, I2=0% inconclusive result	-
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus no additional treatment
	atezolizumab alone vs. no additional treatment	1	-	-	-
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive